Expression of FHIT in primary cultures of human epithelial ovarian tumors and malignant ovarian ascites

Molecular Carcinogenesis

Volumn 24, Issue 3, 1999, Pages 218-225

  Manning, Andrew P ^a   Mes Masson, Anne Marie ^b,c   Seymour, Robert J ^a   Tetrault, Melanie ^b   Provencher, Diane M ^b,c   Tonin, Patricia N ^a,d  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b Institut du Cancer de Montreal   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

3p14; Alternative splicing; FHIT; Ovarian cancer

Indexed keywords

ADULT; AGED; ARTICLE; ASCITES; CANCER CELL CULTURE; CARCINOGENESIS; CONTROLLED STUDY; DNA SEQUENCE; EXON; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INTRON; NORTHERN BLOTTING; OVARY CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACID ANHYDRIDE HYDROLASES; ADULT; AGED; AGED, 80 AND OVER; ASCITES; BLOTTING, NORTHERN; CARCINOMA; CELL LINE, TRANSFORMED; CELLS, CULTURED; CHROMOSOMES, HUMAN, PAIR 3; EPITHELIAL CELLS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; LOSS OF HETEROZYGOSITY; MIDDLE AGED; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PROTEIN BIOSYNTHESIS; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TUMOR CELLS, CULTURED;

EID: 0032925896     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199903)24:3<218::AID-MC8>3.0.CO;2-A     Document Type: Article

References (38)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin. 1996;46:5-27.
2. Nation JG, Krepart GV. Ovarian carcinoma of low malignant potential: Staging and treatment. Am J Obstet Gynecol 1986;154:290-293.
3. Leake JF. Tumors of low malignant potential. Curr Opin Obstet Gyncol 1992;4:81-85.
4. Kok K, Naylor S, Buys CHCM. Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes. Adv Cancer Res 1997;27-92.
5. Linehan WM, Lerman MI, Zbar B. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA 1995; 273:564-570.
6. Ohta M, Innoue H, Cotticelli MG, et al. The FHIT gene, spanning the chromosome 3p 14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 1996;84:587-597.
7. Sozzi G, Veronese ML, Negrini M, et al. The FHIT gene at 3p14.2 is abnormal in lung cancer. Cell 1996;85:17-26.
8. Fong KM, Biesterveld EJ, Virmani A, et al. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res 1997;57:2256-2267.
9. Negrini M, Monaco C, Vorechovsky I, et al. The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res 1996; 56:3173-3179.
10. Pangopoulos I, Pandis N, Thelin S, et al. The FHIT and PTPaseδ genes are deleted in benign proliferative breast disease associated with familial breast cancer and cytogenetic rearrangements of chromosome 3p14. Cancer Res 1996;56:4871-4875.
11. Sozzi G, Alder H, Tornielli S, et al. Aberrant transcripts in merkel cell carcinoma. Cancer Res 1996b;56:2472-2474.
12. Mao I, Fan Y-H, Lotan R, Hong WK. Frequent abnormalities of FHIT a candidate tumor suppressor gene in head and neck cancer cell lines. Cancer Res 1996;56:5128-5131.
13. Kastury K, Baffa R, Druck T, et al. Potential gastrointestinal tumor suppressor locus at the 3p14.2 FRA3B site identified by homozygous deletions in tumor cell lines. Cancer Res 1996; 56:978-983.
14. Man S, Ellis IO, Sibbering M, Blarney RW, Brook JD. High levels of allele loss at the FHIT and ATM genes in non-comedo ductal carcinoma in situ and grade I tubular invasive breast cancers. Cancer Res 1996;56:5484-5489.
15. Yanagisawa K, Kondo M, Osada H, et al. Molecular analysis of the FHIT gene at 3p14.2 in lung cancer cell lines. Cancer Res 1996;56:5579-5582.
16. Virgilio L, Shuster M, Gollin SM, et al. Fhit gene alterations in head and neck squamous cell carcinomas. Proc Natl Acad Sci USA 1996;93:9770-9775.
17. van der Reit-Fox MF, Reteif AE, van Niekerk WA. Chromosome changes in 17 human neoplasms studied with banding. Cancer 1979;44:2108-2119.
18. Whang-Peng J, Knutsen T, Douglass EC, et al. Cytogenetics studies in ovarian cancer. Cancer Genet Cytogenet 1984;11:91-106.
19. Bello MJ, Rey JA. Chromosome aberrations in metastatic ovarian cancer: Relationship with abnormalities in primary tumors. Int J Cancer 1990;45:50-54.
20. Pejovic T, Heim S, Mandahl N, et al. Chromosome aberrations in 35 primary ovarian carcinomas. Genes Chromosomes Cancer 1992;4:58-68.
21. Sato T, Saito II, Morita R, Koi S, Lee H, Nakamura Y. Allelotype of human ovarian cancer. Cancer Res 1991;51:5118-5122.
22. Zheng JP, Robinson WR, Ehlen T, Yu MC, Dubeau L. Distinction of low grade from high grade human ovarian carcinomas on the basis of losses of heterozygosity on chromosomes 3, 6 and 11 and HER/neu gene amplification. Cancer Res 1991;51:4045-4051.
23. Dodson MK, Hartmen LC, Cliby WA, et al. Comparison of loss of heterozygosity patterns in low grade and high grade epithelial ovarian carcinomas. Cancer Res 1993;53:4450-4460.
24. Yang-Feng TL, Han H, Chen KC, et al. Allelic loss in ovarian cancer. Int J Cancer 1993;54:546-551.
25. Lounis H, Mes-Masson A-M, Dion F, et al. Mapping of chromosome arm 3 deletions in human epithelial ovarian tumors. Oncogene 1998;17:2359-2365.
26. Lounis H, Provencher D, Godbout C, Fink D, Milot DJ, Mes-Masson A-M. Primary cultures of normal and tumoral human ovarian epithelium: A powerful tool for basic molecular studies. Exp Cell Res 1994;215:303-309.
27. Kruk PA, Maines-Bandiera SL, Auersperg N. A simplified method to culture human ovarian surface epithelium. Lab Invest 1990;63:132-136.
28. Thiagalingam S, Lisitsyn NA, Hamaguch M, et al. Evaluation of the FHIT gene in colorectal cancers. Cancer Res 1996;56:2936-2939.
29. Van den Berg A, Draaijers TG, Kok K, et al. Normal FHIT transcripts in renal cell cancer and lung cancer derived cell lines, including a cell line with a homozygous deletion in the FRA3B region. Genes Chromosomes Cancer 1997;19:220-227.
30. Wang L, Darling J, Zhang JS, et al. Frequent homozygous deletions in the FRA3B region in tumor cell lines still leave the FHIT exons intact. Oncogene 1998;16:635-642.
31. Greenspan DL, Connolly DC, Wu R, et al. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Res 1997;57:4692-4698.
32. Zimonjic DB, Druck T, Ohta M, et al. Positions of chromosome 3p14.2 fragile sites (FRA3B) within the FHIT gene. Cancer Res 1997;57:1166-1170.
33. Druck T, Hadaczek P, Fu TB, et al. Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res 1996;57:504-512.
34. Wang L, Paradee W, Mullins C, et al. Aphidicolin-induced FRA3B breakpoints cluster in two distinct regions. Genomics 1997;41:485-488.
35. Boldog F, Gemmill RM, West J, et al. Chromosome 3p14 homozygous deletions and sequence analysis of FRA3B. Hum Mol Genet 1997;6:193-203.
36. Hendricks DT, Taylor R, Reed M, Birrer MJ. FHIT gene expression in human ovarian, endometrial, and cervical cancer cell lines. Cancer Res 1997;57:2112-2115.
37. Pangopoulos I, Thelin S, Mertens F, Mitelman F, Aman P. Variable FHIT transcripts in non-neoplastic tissues. Genes Chromosomes Cancer 1997;19:215-219.
38. Gayther SA, Barski P, Batley SJ, et al. Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumors. Oncogene 1997;15:2119-2126.